Cargando…

Cell‐based therapies for the treatment of rheumatoid arthritis

Autoimmune diseases, including rheumatoid arthritis that is the most prevalent rheumatic autoimmune disorder, affect autologous connective tissues caused by the breakdown of the self‐tolerance mechanisms of the immune system. During the last two decades, cell‐based therapy, including stem cells and...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghaddam, Maryam Zare, Mousavi, Mohammad Javad, Ghotloo, Somayeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664399/
https://www.ncbi.nlm.nih.gov/pubmed/38018576
http://dx.doi.org/10.1002/iid3.1091
_version_ 1785148729752289280
author Moghaddam, Maryam Zare
Mousavi, Mohammad Javad
Ghotloo, Somayeh
author_facet Moghaddam, Maryam Zare
Mousavi, Mohammad Javad
Ghotloo, Somayeh
author_sort Moghaddam, Maryam Zare
collection PubMed
description Autoimmune diseases, including rheumatoid arthritis that is the most prevalent rheumatic autoimmune disorder, affect autologous connective tissues caused by the breakdown of the self‐tolerance mechanisms of the immune system. During the last two decades, cell‐based therapy, including stem cells and none‐stem cells has been increasingly considered as a therapeutic option in various diseases. This is partly due to the unique properties of stem cells that divide and differentiate from the specialized cells in the damaged tissue. Moreover, stem cells and none‐stem cells, impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders. In the present review, the efficacy of cell‐based therapy with four main types of stem cells, including mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, and human amniotic membrane cells, as well as none‐stem cells, including regulatory T cells, chimeric antigen receptor T cells, and tolerogenic dendritic cells will be evaluated. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell and none‐stem cell origin, conditioning regimen, limitations, and complications will be discussed.
format Online
Article
Text
id pubmed-10664399
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106643992023-11-22 Cell‐based therapies for the treatment of rheumatoid arthritis Moghaddam, Maryam Zare Mousavi, Mohammad Javad Ghotloo, Somayeh Immun Inflamm Dis Review Article Autoimmune diseases, including rheumatoid arthritis that is the most prevalent rheumatic autoimmune disorder, affect autologous connective tissues caused by the breakdown of the self‐tolerance mechanisms of the immune system. During the last two decades, cell‐based therapy, including stem cells and none‐stem cells has been increasingly considered as a therapeutic option in various diseases. This is partly due to the unique properties of stem cells that divide and differentiate from the specialized cells in the damaged tissue. Moreover, stem cells and none‐stem cells, impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders. In the present review, the efficacy of cell‐based therapy with four main types of stem cells, including mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, and human amniotic membrane cells, as well as none‐stem cells, including regulatory T cells, chimeric antigen receptor T cells, and tolerogenic dendritic cells will be evaluated. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell and none‐stem cell origin, conditioning regimen, limitations, and complications will be discussed. John Wiley and Sons Inc. 2023-11-22 /pmc/articles/PMC10664399/ /pubmed/38018576 http://dx.doi.org/10.1002/iid3.1091 Text en © 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Moghaddam, Maryam Zare
Mousavi, Mohammad Javad
Ghotloo, Somayeh
Cell‐based therapies for the treatment of rheumatoid arthritis
title Cell‐based therapies for the treatment of rheumatoid arthritis
title_full Cell‐based therapies for the treatment of rheumatoid arthritis
title_fullStr Cell‐based therapies for the treatment of rheumatoid arthritis
title_full_unstemmed Cell‐based therapies for the treatment of rheumatoid arthritis
title_short Cell‐based therapies for the treatment of rheumatoid arthritis
title_sort cell‐based therapies for the treatment of rheumatoid arthritis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664399/
https://www.ncbi.nlm.nih.gov/pubmed/38018576
http://dx.doi.org/10.1002/iid3.1091
work_keys_str_mv AT moghaddammaryamzare cellbasedtherapiesforthetreatmentofrheumatoidarthritis
AT mousavimohammadjavad cellbasedtherapiesforthetreatmentofrheumatoidarthritis
AT ghotloosomayeh cellbasedtherapiesforthetreatmentofrheumatoidarthritis